Biogen Inc.

NasdaqGS BIIB

Biogen Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 17.17%

Biogen Inc. Net Income Margin is 17.17% for the Trailing 12 Months (TTM) ending September 30, 2024, a 17.40% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Biogen Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 14.63%, a -45.52% change year over year.
Biogen Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 26.85%, a 92.82% change year over year.
Biogen Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 13.93%, a -60.92% change year over year.
Biogen Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 35.63%, a -6.01% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: BIIB

Biogen Inc.

CEO	Mr. Christopher A. Viehbacher
IPO Date	Sept. 17, 1991
Location	United States
Headquarters	225 Binney Street
Employees	7,570
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years